Cyclopharm doses first French patients with technegas in PRONOSPECT trial

Cyclopharm (ASX:CYC) has dosed its first French patients with its technegas lung imaging product in an ongoing trial. While the company received FDA approval in the U.S. last year, the company is conducting its ‘PRONOSPECT’ trial across 13 facilities in France equipped to manage nuclear medicine products.

Technegas is composed of ‘ultrafine particles of Tc-99m-labeled carbon particles, which constitute radioactive element technetium – wherein ‘technegas’ gets its name.

Ultimately, the particles are breathed in, and within several breaths (per extant advertising materials online) technegas allows doctor-operators to visualise a patients’ lungs without the need for PET scans and other such pathways.

Being scanned for: Pulmonary embolism (PE) and venous thromboembolism (VTE).

At any rate, Tuesday’s news reflects a drop in the ocean compared to overall study size – the first 15 patients of over 650 have now been dosed with technegas.

With the study, the company is ultimately hoping to supply more data to the world on the efficacy of technegas, and perhaps more importantly, how hospitals and clinics can more easily use it.

“This study validates Technegas’ capabilities in advanced pulmonary diagnostics and aligns with our commitment to improving global healthcare outcomes,” Cyclopharm CEO James McBrayer said.

“We look forward to sharing the trial results, which we believe will have implications for patient care and our commercial strategy.”

CYC last traded at $1.65/sh.

Join the discussion: See what HotCopper users are saying about Cyclopharm and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.